
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pentoxifylline
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Poolbeg Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Poolbeg Pharma PLC Announces Option Agreement to Acquire Orphan Drug Candidate
Details : Through the agreement with Silk Road Therapeutics to acquire novel topical muco-adherent formulation of Trental (pentoxifylline), for oral ulcers in patients suffering from behcet's disease.
Product Name : Trental
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 30, 2024
Lead Product(s) : Pentoxifylline
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Poolbeg Pharma
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pentoxifylline
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Soligenix
Deal Size : Undisclosed
Deal Type : Agreement
Details : The option agreement grants Soligenix the right to acquire a novel topical formulation of SRT001 (pentoxifylline), a non-biological anti-TNF-alpha inhibitor, for the treatment of mucocutaneous ulcers in patient's suffering from Behçet's Disease (BD).
Product Name : Trental
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 01, 2023
Lead Product(s) : Pentoxifylline
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Soligenix
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pentoxifylline
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers
Details : Pentoxifylline is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Behcet Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 04, 2019
Lead Product(s) : Pentoxifylline
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
